Microbot Medical (MBOT) to Release Quarterly Earnings on Wednesday

Key Points

• Microbot Medical (MBOT) will report quarterly results after market close on Wednesday, May 13; analysts expect EPS of ($0.08) and revenue of $0.30M, after the company posted ($0.04) EPS and topped estimates in the prior quarter.
• Shares opened at $2.10 with a market cap of $141M and a 52‑week range of $1.60–$4.67; the consensus analyst rating is Moderate Buy with an average price target of $7.50, and institutional investors (about 16.3% ownership) have recently added positions.

Microbot Medical (NASDAQ:MBOT - Get Free Report) is expected to be announcing its results after the market closes on Wednesday, May 13th. Analysts expect the company to announce earnings of ($0.08) per share and revenue of $0.30 million for the quarter.

Microbot Medical (NASDAQ:MBOT - Get Free Report) last announced its quarterly earnings results on Friday, March 27th. The biotechnology company reported ($0.04) earnings per share for the quarter, topping analysts' consensus estimates of ($0.06) by $0.02. On average, analysts expect Microbot Medical to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Microbot Medical Stock Performance

MBOT opened at $2.10 on Wednesday. The company has a market cap of $141.04 million, a PE ratio of -7.24 and a beta of 1.06. The stock has a 50-day moving average of $2.41 and a 200-day moving average of $2.23. Microbot Medical has a 52-week low of $1.60 and a 52-week high of $4.67.

Institutional Trading of Microbot Medical

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. CIBC Bancorp USA Inc. bought a new position in Microbot Medical in the 3rd quarter worth approximately $4,435,000. Vanguard Group Inc. boosted its position in shares of Microbot Medical by 14.3% in the third quarter. Vanguard Group Inc. now owns 2,343,561 shares of the biotechnology company's stock valued at $7,148,000 after acquiring an additional 292,923 shares during the period. Geode Capital Management LLC boosted its position in shares of Microbot Medical by 54.4% in the fourth quarter. Geode Capital Management LLC now owns 761,995 shares of the biotechnology company's stock valued at $1,524,000 after acquiring an additional 268,609 shares during the period. 683 Capital Management LLC acquired a new stake in shares of Microbot Medical in the fourth quarter worth $512,000. Finally, AlphaCentric Advisors LLC acquired a new stake in shares of Microbot Medical in the fourth quarter worth $400,000. Institutional investors and hedge funds own 16.30% of the company's stock.

Analysts Set New Price Targets

MBOT has been the subject of several analyst reports. Wall Street Zen lowered Microbot Medical from a "sell" rating to a "strong sell" rating in a report on Saturday. B. Riley Financial initiated coverage on shares of Microbot Medical in a research report on Tuesday, February 10th. They issued a "buy" rating on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Microbot Medical in a research note on Friday, April 10th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $12.00 price objective on shares of Microbot Medical in a report on Tuesday, April 14th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $7.50.

Microbot Medical Company Profile

Microbot Medical Inc NASDAQ: MBOT is a medical device company focused on the design, development and commercialization of micro-robotic platforms for minimally invasive procedures. Leveraging proprietary microbot technology, the company aims to navigate complex vascular and luminal pathways within the body to deliver therapy, retrieve tissue samples or perform diagnostic tasks in a precise, targeted manner.

Microbot Medical operates two primary technology divisions. Its endovascular platform is designed to traverse blood vessels and deliver clot-retrieval systems, drug payloads or cell-based therapies directly at the site of vascular injury, with applications in acute ischemic stroke and peripheral artery disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.